Cosmo Pharmaceuticals N.V.

Informe acción SWX:COPN

Capitalización de mercado: CHF 993.2m

Salud financiera de hoja de balance de Cosmo Pharmaceuticals

Salud financiera controles de criterios 6/6

Cosmo Pharmaceuticals tiene un patrimonio de accionistas total de €505.4M y una deuda total de €559.0K, lo que sitúa su ratio deuda-patrimonio en 0.1%. Sus activos y pasivos totales son €638.3M y €132.9M respectivamente. El BAIT de Cosmo Pharmaceuticals es de €86.0M, por lo que su ratio de cobertura de intereses es de 154.4. Tiene efectivo e inversiones a corto plazo que ascienden a €133.4M.

Información clave

0.1%

Ratio deuda-patrimonio

€559.00k

Deuda

Ratio de cobertura de intereses154.4x
Efectivo€133.41m
Patrimonio€505.39m
Total pasivo€132.87m
Activos totales€638.25m

Actualizaciones recientes sobre salud financiera

Recent updates

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Nov 22
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

May 20
Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

Apr 03
Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Mar 07
When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€183.6M) de COPN superan a sus pasivos a corto plazo (€37.9M).

Pasivo a largo plazo: Los activos a corto plazo de COPN (€183.6M) superan a sus pasivos a largo plazo (€95.0M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: COPN tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de COPN ha pasado de 38.9% a 0.1% en los últimos 5 años.

Cobertura de la deuda: La deuda de COPN está bien cubierta por el flujo de caja operativo (20988.6%).

Cobertura de intereses: Los pagos de intereses de la deuda de COPN están bien cubiertos por el BAIT (154.4x cobertura).


Hoja de balance


Descubre empresas con salud financiera